Walleye Capital
ASBPW

Walleye Capital’s Aspire Biopharma Warrant ASBPW Stock Holding History

Walleye Capital’s Portfolio ASBPW Stock Details ASBPW Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-46,560
Closed -$1.97K – 5742
2024
Q3 		$1.97K Hold
46,560
– – ﹤0.01% 5091
2024
Q2 		$2.09K Hold
46,560
– – ﹤0.01% 5418
2024
Q1 		$1.4K Hold
46,560
– – ﹤0.01% 5297
2023
Q4 		$2.79K Hold
46,560
– – ﹤0.01% 4723
2023
Q3 		$2.36K Buy
46,560
+14,560
+46% +$1.18K ﹤0.01% 4702
2023
Q2 		$1.6K Buy
+32,000
New +$1.17K ﹤0.01% 4167

Other funds holding ASBPW

AC
Athos Capital Hong Kong $324M AUM 16.62% 1-Year Est. Return
HCM
Highbridge Capital Management New York $3.09B AUM 31.19% 1-Year Est. Return
SCM
Saba Capital Management New York $3.62B AUM 13% 1-Year Est. Return
LA
Linden Advisors New York $17.9B AUM 1.72% 1-Year Est. Return
AA
AQR Arbitrage Greenwich, Connecticut $6.09B AUM 27.01% 1-Year Est. Return
PC
Periscope Capital Toronto, Ontario, Canada $902M AUM 6.51% 1-Year Est. Return
SC
Sculptor Capital New York $9.61B AUM 27.49% 1-Year Est. Return
Verition Fund Management
Verition Fund Management Greenwich, Connecticut $15.4B AUM 30.69% 1-Year Est. Return
WAM
Wolverine Asset Management Chicago, Illinois $10.4B AUM 4.78% 1-Year Est. Return
Barclays
Barclays London, United Kingdom $416B AUM 33.63% 1-Year Est. Return

Walleye Capital's ASBPW Position: Q4 2024 in Review

Walleye Capital sold out of Aspire Biopharma Warrant (ASBPW) in Q4 2024, closing a stake of 46,560 shares — an estimated $1.97K sold.

Walleye Capital first reported a position in ASBPW in Q2 2023 and held it in 6 quarters. The position peaked at $2.79K in Q4 2023. 26 funds tracked by Wall St. Rank hold ASBPW as of Q4 2024.

  • Walleye Capital reported no remaining Aspire Biopharma Warrant position as of Q4 2024 after selling out during the quarter.
  • Walleye Capital sold 46,560 Aspire Biopharma Warrant shares in Q4 2024, an estimated $1.97K.
  • Walleye Capital first reported a position in Aspire Biopharma Warrant in Q2 2023 and held it in 6 quarters.
  • Walleye Capital's Aspire Biopharma Warrant position peaked at $2.79K in Q4 2023.
  • 26 funds tracked by Wall St. Rank held Aspire Biopharma Warrant as of Q4 2024.

Based on Walleye Capital's 13F filing for Q4 2024, filed 13 Feb 2025.